Opko Health Inc (OPK) 9.63 $OPK
The Market's 10 Best Stocks
Dan Caplinger, The Motley Fool - Motley Fool - Sun Dec 21, 7:02AM CST
Source: Wikimedia Commons. Investors are always searching for the best possible stocks. That's because if you can identify a winning stock before it takes off, it can have a life-changing impact on your finances. In order to find those stocks,...
NFLX: 342.10 (+5.67), NEU: 405.00 (+5.94), MNST: 112.56 (+0.52), OPK: 9.63 (+0.21), GMCR: 137.65 (+1.10), ALXN: 181.96 (+3.09), ILMN: 186.22 (+2.72), AAPL: 112.01 (-0.53), REGN: 400.12 (+6.07), PCLN: 1,149.78 (+2.17)
Seeking Alpha's Biotech Weekly: A Merck Purchase, Spectacular Auspex, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Dec 19, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. What should the Seeking Alpha community be reading and writing about? Please leave...
SPHS: 0.46 (+0.02), ASPX: 49.93 (-0.10), MDVN: 99.23 (+1.23), CYCC: 0.69 (+0.01), OPK: 9.63 (+0.21), NLNK: 39.08 (+1.36), JUNO: 39.99 (+2.71), REGN: 400.12 (+6.07), MYGN: 36.50 (+0.28), PFE: 31.42 (-0.03), IMGN: 5.90 (+0.13), AMGN: 160.67 (+3.15), GSK: 42.85 (+0.11), BMY: 59.15 (-0.01), BLRX: 1.68 (-0.01), OREX: 5.98 (+0.01), DVA: 76.06 (+0.07), BLCM: 19.30 (+0.18), CBST: 100.29 (-0.09), GILD: 91.29 (+1.84), GERN: 3.06 (+0.05), MRK: 57.46 (+0.25), NVS: 93.91 (+0.66)
Pfizer, Inc. Invests in Growth... Literally
Todd Campbell, The Motley Fool - Motley Fool - Wed Dec 17, 7:06AM CST
Source: Pfizer Pfizer Inc . locked up commercial rights to Opko Health 's long-lasting human growth hormone in a deal worth hundreds of millions of dollars. The agreement helps insulate Pfizer's existing HGH drug from potential competition and...
GILD: 91.29 (+1.84), OPK: 9.63 (+0.21), PFE: 31.42 (-0.03), TEVA: 57.09 (+0.33)
OPKO Up on Announcing Global Partnership with Pfizer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 4:00PM CST
OPKO Health's (OPK) shares gained around 8.3% after announcing a worldwide agreement with Pfizer (PFE).
BIIB: 340.89 (+5.13), OPK: 9.63 (+0.21), PFE: 31.42 (-0.03), AMGN: 160.67 (+3.15)
Pfizer Ponies Up to Develop Long-acting Growth Hormone
at The Street - Tue Dec 16, 10:38AM CST
Opko gains $295 million up front for global license to develop, market long-acting HGH.
OPK: 9.63 (+0.21), PFE: 31.42 (-0.03), TEVA: 57.09 (+0.33)
Strength Seen in Opko Health (OPK): Stock Rises 8.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 8:25AM CST
Opko Health (OPK) was a big mover last session, with shares rising over 8% on the day.
ETRM: 1.40 (-0.01), FLDM: 32.31 (+0.30), OPK: 9.63 (+0.21), EW: 130.75 (+1.17)
Pfizer licenses Opko's hGH
at Investor's Business Daily - Mon Dec 15, 5:46PM CST
The drugmaker agreed to pay biotech OpkoHealth (OPK) $295 mil upfront and up to $275 mil in milestone payments if its human-growth drug candidate passes through all the regulatory hurdles. The drug is currently in late-stage testing for adults and is...
OPK: 9.63 (+0.21), PFE: 31.42 (-0.03)
Jim Cramer Says Twitter Needs Better Management for Stock to Rise
at The Street - Mon Dec 15, 11:05AM CST
TheStreet's Jim Cramer says that Twitter has the potential to be a good stock, if its management ran the business more effectively.
OPK: 9.63 (+0.21), PFE: 31.42 (-0.03), TWTR: 37.61 (+0.04)
Pfizer Licenses Opko's Long-Acting Growth Hormone
at Investor's Business Daily - Mon Dec 15, 11:01AM CST
Biotech Opko Health found a big-pharma partner for its human-growth drug candidate in the form of Pfizer on Monday in a deal that could be worth as much as $570 million. Opko Health (OPK) stock was near 9, up 9% in morning trading -- a more than...
TSRO: 36.80 (+0.57), OPK: 9.63 (+0.21), PFE: 31.42 (-0.03)
Why Opko Health Inc.'s Shares Got a Shot to the Arm Today
Alex Planes, The Motley Fool - Motley Fool - Mon Dec 15, 9:10AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Opko Health are trading 11% higher this...
OPK: 9.63 (+0.21), PFE: 31.42 (-0.03)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 8:12AM CST
FRO: 2.43 (-0.01), TLM: 7.84 (unch), SPHS: 0.46 (+0.02), HGSH: 4.60 (-0.06), SN: 9.91 (-0.71), NBG: 1.95 (+0.06), AXAS: 3.16 (-0.13), RVBD: 20.35 (+0.01), OPK: 9.63 (+0.21), ANTH: 1.48 (unch), ONVO: 6.84 (+0.03), KEG: 1.73 (+0.01), CALA: 22.33 (+1.16), XCO: 2.38 (-0.03), CRUS: 23.60 (unch), ARCP: 8.33 (unch)
Pfizer adds to pipeline with Opko deal
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 7:56AM CST
OPK: 9.63 (+0.21), PFE: 31.42 (-0.03)
OPKO and Pfizer Enter into Global Agreement for OPKO's Long-Acting Human Growth Hormone (hGH-CTP)
Business Wire - Mon Dec 15, 7:00AM CST
--hGH-CTP has potential to reduce dosing frequency of human growth hormone to single weekly injection from current standard of daily injection
OPK: 9.63 (+0.21), PFE: 31.42 (-0.03)
Tiger Media Announces Agreement to Acquire Interactive Data, LLC
Business Wire - Mon Dec 15, 7:00AM CST
Tiger Media, Inc. ("Tiger Media" or the "Company"
(NYSE MKT: IDI), a Shanghai-based multi-platform media company, today announced that it has entered into a definitive agreement to acquire The Best One, Inc. ("TBO" , parent company of U.S.-based data solutions provider Interactive Data, LLC ("Interactive Data" (the "Acquisition" . Interactive Data is headquartered in Atlanta, GA and has its primary technology office in Seattle, WA.
IDI: 0.72 (-0.07), OPK: 9.63 (+0.21)
Secondary Hyperparathyroidism - Pipeline Review, H2 2014
M2 - Fri Dec 12, 3:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/6x9vld/secondary) has announced the addition of the "Secondary Hyperparathyroidism - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Secondary Hyperparathyroidism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Secondary Hyperparathyroidism and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Secondary Hyperparathyroidism - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Secondary Hyperparathyroidism pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen Inc. - Nektar Therapeutics - Astellas Pharma Inc. - Mitsubishi Tanabe Pharma Corporation - OPKO Health, Inc. - NPS Pharmaceuticals, Inc. - Deltanoid Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/6x9vld/secondary
OPK: 9.63 (+0.21), NPSP: 35.06 (+1.18), AMGN: 160.67 (+3.15), NKTR: 15.02 (+0.23)
RedHill submits MAA for ondansetron
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 11:38AM CST
INSY: 41.52 (+0.51), TSRO: 36.80 (+0.57), HRTX: 9.75 (+0.02), RDHL: 12.22 (-0.13), GWPH: 68.08 (+1.82), OPK: 9.63 (+0.21), GALE: 1.49 (-0.02)
Biotech Stocks Technical Coverage - OPKO Health, IsoRay, Nanosphere, Amicus Therapeutics, and Isis Pharma
PR Newswire - Thu Dec 04, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: OPKO Health Inc. (NYSE: OPK), IsoRay Inc. (NYSE MKT: ISR), Nanosphere Inc. (NASDAQ: NSPH), Amicus Therapeutics Inc. (NASDAQ: FOLD), and Isis Pharmaceuticals Inc. (NASDAQ: ISIS). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Wednesday, December 03, 2014, the NASDAQ Composite ended at 4,774.47, up 0.39%, the Dow Jones Industrial Average advanced 0.18%, to finish the day at 17,912.62, and the S&P 500 closed at 2,074.33, up 0.38%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 812.13, up 0.15%, with the index also advancing 9.64% in the previous three months. Register for your complimentary reports on these five stocks at:
ISIS: 59.49 (+1.88), OPK: 9.63 (+0.21), ISR: 1.54 (+0.04), FOLD: 7.94 (+0.06), NSPH: 0.39 (-0.01)
OPKO Health to Present at the Oppenheimer 25th Annual Healthcare Conference
Business Wire - Wed Dec 03, 7:30AM CST
OPKO Health, Inc. (NYSE:OPK) today announced that senior management will present at the Oppenheimer 25th Annual Healthcare Conference on Wednesday, December 10, 2014 at 10:20 AM (ET).
OPK: 9.63 (+0.21)
Parkinson's Disease - Pipeline Review, H2 2014
M2 - Tue Dec 02, 5:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/7k9xvt/parkinsons) has announced the addition of the "Parkinson's Disease - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Parkinson's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Parkinson's Disease - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Parkinson's Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: 169 companies are cited in this text including: - Amicus Therapeutics, Inc. - AstraZeneca PLC - Bial - Portela & Ca, S.A. - Calico LLC - Cardax Pharmaceuticals, Inc. - Edison Pharmaceuticals, Inc. - GlaxoSmithKline plc - GliaCure Inc. - H. Lundbeck A/S - Io Therapeutics, Inc. - Iproteos S.L. - Jeil Pharmaceutical Co., Ltd. - KineMed, Inc. - Medeia Therapeutics Ltd. - Motac Neuroscience Ltd - Netherlands Translational Research Center B.V. - nLife Therapeutics, S.L. - Novartis AG - OPKO Health, Inc. - Orion Oyj - Peptron, Inc. - Pfizer Inc. - QR Pharma, Inc. - QRxPharma Limited - Raptor Pharmaceuticals Corp. - SanBio, Inc. - Saneron CCEL Therapeutics, Inc. - Stelic Institute & Co. - Sumitomo Dainippon Pharma Co., Ltd. For more information visit http://www.researchandmarkets.com/research/7k9xvt/parkinsons
RPTP: 9.34 (+0.56), KNMD: (), OPK: 9.63 (+0.21), PFE: 31.42 (-0.03), AZN: 70.44 (+0.26), GSK: 42.85 (+0.11), FOLD: 7.94 (+0.06), NVS: 93.91 (+0.66)
Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/vkx899/hyperphosphatemia) has announced the addition of the "Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hyperphosphatemia In Chronic Kidney Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperphosphatemia In Chronic Kidney Disease and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hyperphosphatemia In Chronic Kidney Disease - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hyperphosphatemia In Chronic Kidney Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen - OPKO Health - Panion & Bf Biotech - Sanofi - Vifor Pharma For more information visit http://www.researchandmarkets.com/research/vk...osphatemia
OPK: 9.63 (+0.21), AMGN: 160.67 (+3.15)
The Market's 10 Best Stocks
Dan Caplinger, The Motley Fool - Motley Fool - Sun Dec 21, 7:02AM CST
Source: Wikimedia Commons. Investors are always searching for the best possible stocks. That's because if you can identify a winning stock before it takes off, it can have a life-changing impact on your finances. In order to find those stocks,...
NFLX: 342.10 (+5.67), NEU: 405.00 (+5.94), MNST: 112.56 (+0.52), OPK: 9.63 (+0.21), GMCR: 137.65 (+1.10), ALXN: 181.96 (+3.09), ILMN: 186.22 (+2.72), AAPL: 112.01 (-0.53), REGN: 400.12 (+6.07), PCLN: 1,149.78 (+2.17)
Seeking Alpha's Biotech Weekly: A Merck Purchase, Spectacular Auspex, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Dec 19, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. What should the Seeking Alpha community be reading and writing about? Please leave...
SPHS: 0.46 (+0.02), ASPX: 49.93 (-0.10), MDVN: 99.23 (+1.23), CYCC: 0.69 (+0.01), OPK: 9.63 (+0.21), NLNK: 39.08 (+1.36), JUNO: 39.99 (+2.71), REGN: 400.12 (+6.07), MYGN: 36.50 (+0.28), PFE: 31.42 (-0.03), IMGN: 5.90 (+0.13), AMGN: 160.67 (+3.15), GSK: 42.85 (+0.11), BMY: 59.15 (-0.01), BLRX: 1.68 (-0.01), OREX: 5.98 (+0.01), DVA: 76.06 (+0.07), BLCM: 19.30 (+0.18), CBST: 100.29 (-0.09), GILD: 91.29 (+1.84), GERN: 3.06 (+0.05), MRK: 57.46 (+0.25), NVS: 93.91 (+0.66)
Pfizer, Inc. Invests in Growth... Literally
Todd Campbell, The Motley Fool - Motley Fool - Wed Dec 17, 7:06AM CST
Source: Pfizer Pfizer Inc . locked up commercial rights to Opko Health 's long-lasting human growth hormone in a deal worth hundreds of millions of dollars. The agreement helps insulate Pfizer's existing HGH drug from potential competition and...
GILD: 91.29 (+1.84), OPK: 9.63 (+0.21), PFE: 31.42 (-0.03), TEVA: 57.09 (+0.33)
OPKO Up on Announcing Global Partnership with Pfizer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 4:00PM CST
OPKO Health's (OPK) shares gained around 8.3% after announcing a worldwide agreement with Pfizer (PFE).
BIIB: 340.89 (+5.13), OPK: 9.63 (+0.21), PFE: 31.42 (-0.03), AMGN: 160.67 (+3.15)
Pfizer Ponies Up to Develop Long-acting Growth Hormone
at The Street - Tue Dec 16, 10:38AM CST
Opko gains $295 million up front for global license to develop, market long-acting HGH.
OPK: 9.63 (+0.21), PFE: 31.42 (-0.03), TEVA: 57.09 (+0.33)
Strength Seen in Opko Health (OPK): Stock Rises 8.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 8:25AM CST
Opko Health (OPK) was a big mover last session, with shares rising over 8% on the day.
ETRM: 1.40 (-0.01), FLDM: 32.31 (+0.30), OPK: 9.63 (+0.21), EW: 130.75 (+1.17)
Pfizer licenses Opko's hGH
at Investor's Business Daily - Mon Dec 15, 5:46PM CST
The drugmaker agreed to pay biotech OpkoHealth (OPK) $295 mil upfront and up to $275 mil in milestone payments if its human-growth drug candidate passes through all the regulatory hurdles. The drug is currently in late-stage testing for adults and is...
OPK: 9.63 (+0.21), PFE: 31.42 (-0.03)
Jim Cramer Says Twitter Needs Better Management for Stock to Rise
at The Street - Mon Dec 15, 11:05AM CST
TheStreet's Jim Cramer says that Twitter has the potential to be a good stock, if its management ran the business more effectively.
OPK: 9.63 (+0.21), PFE: 31.42 (-0.03), TWTR: 37.61 (+0.04)
Pfizer Licenses Opko's Long-Acting Growth Hormone
at Investor's Business Daily - Mon Dec 15, 11:01AM CST
Biotech Opko Health found a big-pharma partner for its human-growth drug candidate in the form of Pfizer on Monday in a deal that could be worth as much as $570 million. Opko Health (OPK) stock was near 9, up 9% in morning trading -- a more than...
TSRO: 36.80 (+0.57), OPK: 9.63 (+0.21), PFE: 31.42 (-0.03)
Why Opko Health Inc.'s Shares Got a Shot to the Arm Today
Alex Planes, The Motley Fool - Motley Fool - Mon Dec 15, 9:10AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Opko Health are trading 11% higher this...
OPK: 9.63 (+0.21), PFE: 31.42 (-0.03)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 8:12AM CST
FRO: 2.43 (-0.01), TLM: 7.84 (unch), SPHS: 0.46 (+0.02), HGSH: 4.60 (-0.06), SN: 9.91 (-0.71), NBG: 1.95 (+0.06), AXAS: 3.16 (-0.13), RVBD: 20.35 (+0.01), OPK: 9.63 (+0.21), ANTH: 1.48 (unch), ONVO: 6.84 (+0.03), KEG: 1.73 (+0.01), CALA: 22.33 (+1.16), XCO: 2.38 (-0.03), CRUS: 23.60 (unch), ARCP: 8.33 (unch)
Pfizer adds to pipeline with Opko deal
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 7:56AM CST
OPK: 9.63 (+0.21), PFE: 31.42 (-0.03)
OPKO and Pfizer Enter into Global Agreement for OPKO's Long-Acting Human Growth Hormone (hGH-CTP)
Business Wire - Mon Dec 15, 7:00AM CST
--hGH-CTP has potential to reduce dosing frequency of human growth hormone to single weekly injection from current standard of daily injection
OPK: 9.63 (+0.21), PFE: 31.42 (-0.03)
Tiger Media Announces Agreement to Acquire Interactive Data, LLC
Business Wire - Mon Dec 15, 7:00AM CST
Tiger Media, Inc. ("Tiger Media" or the "Company"
(NYSE MKT: IDI), a Shanghai-based multi-platform media company, today announced that it has entered into a definitive agreement to acquire The Best One, Inc. ("TBO" , parent company of U.S.-based data solutions provider Interactive Data, LLC ("Interactive Data" (the "Acquisition" . Interactive Data is headquartered in Atlanta, GA and has its primary technology office in Seattle, WA. IDI: 0.72 (-0.07), OPK: 9.63 (+0.21)
Secondary Hyperparathyroidism - Pipeline Review, H2 2014
M2 - Fri Dec 12, 3:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/6x9vld/secondary) has announced the addition of the "Secondary Hyperparathyroidism - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Secondary Hyperparathyroidism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Secondary Hyperparathyroidism and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Secondary Hyperparathyroidism - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Secondary Hyperparathyroidism pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen Inc. - Nektar Therapeutics - Astellas Pharma Inc. - Mitsubishi Tanabe Pharma Corporation - OPKO Health, Inc. - NPS Pharmaceuticals, Inc. - Deltanoid Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/6x9vld/secondary
OPK: 9.63 (+0.21), NPSP: 35.06 (+1.18), AMGN: 160.67 (+3.15), NKTR: 15.02 (+0.23)
RedHill submits MAA for ondansetron
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 11:38AM CST
INSY: 41.52 (+0.51), TSRO: 36.80 (+0.57), HRTX: 9.75 (+0.02), RDHL: 12.22 (-0.13), GWPH: 68.08 (+1.82), OPK: 9.63 (+0.21), GALE: 1.49 (-0.02)
Biotech Stocks Technical Coverage - OPKO Health, IsoRay, Nanosphere, Amicus Therapeutics, and Isis Pharma
PR Newswire - Thu Dec 04, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: OPKO Health Inc. (NYSE: OPK), IsoRay Inc. (NYSE MKT: ISR), Nanosphere Inc. (NASDAQ: NSPH), Amicus Therapeutics Inc. (NASDAQ: FOLD), and Isis Pharmaceuticals Inc. (NASDAQ: ISIS). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Wednesday, December 03, 2014, the NASDAQ Composite ended at 4,774.47, up 0.39%, the Dow Jones Industrial Average advanced 0.18%, to finish the day at 17,912.62, and the S&P 500 closed at 2,074.33, up 0.38%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 812.13, up 0.15%, with the index also advancing 9.64% in the previous three months. Register for your complimentary reports on these five stocks at:
ISIS: 59.49 (+1.88), OPK: 9.63 (+0.21), ISR: 1.54 (+0.04), FOLD: 7.94 (+0.06), NSPH: 0.39 (-0.01)
OPKO Health to Present at the Oppenheimer 25th Annual Healthcare Conference
Business Wire - Wed Dec 03, 7:30AM CST
OPKO Health, Inc. (NYSE:OPK) today announced that senior management will present at the Oppenheimer 25th Annual Healthcare Conference on Wednesday, December 10, 2014 at 10:20 AM (ET).
OPK: 9.63 (+0.21)
Parkinson's Disease - Pipeline Review, H2 2014
M2 - Tue Dec 02, 5:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/7k9xvt/parkinsons) has announced the addition of the "Parkinson's Disease - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Parkinson's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Parkinson's Disease - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Parkinson's Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: 169 companies are cited in this text including: - Amicus Therapeutics, Inc. - AstraZeneca PLC - Bial - Portela & Ca, S.A. - Calico LLC - Cardax Pharmaceuticals, Inc. - Edison Pharmaceuticals, Inc. - GlaxoSmithKline plc - GliaCure Inc. - H. Lundbeck A/S - Io Therapeutics, Inc. - Iproteos S.L. - Jeil Pharmaceutical Co., Ltd. - KineMed, Inc. - Medeia Therapeutics Ltd. - Motac Neuroscience Ltd - Netherlands Translational Research Center B.V. - nLife Therapeutics, S.L. - Novartis AG - OPKO Health, Inc. - Orion Oyj - Peptron, Inc. - Pfizer Inc. - QR Pharma, Inc. - QRxPharma Limited - Raptor Pharmaceuticals Corp. - SanBio, Inc. - Saneron CCEL Therapeutics, Inc. - Stelic Institute & Co. - Sumitomo Dainippon Pharma Co., Ltd. For more information visit http://www.researchandmarkets.com/research/7k9xvt/parkinsons
RPTP: 9.34 (+0.56), KNMD: (), OPK: 9.63 (+0.21), PFE: 31.42 (-0.03), AZN: 70.44 (+0.26), GSK: 42.85 (+0.11), FOLD: 7.94 (+0.06), NVS: 93.91 (+0.66)
Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/vkx899/hyperphosphatemia) has announced the addition of the "Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hyperphosphatemia In Chronic Kidney Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperphosphatemia In Chronic Kidney Disease and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hyperphosphatemia In Chronic Kidney Disease - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hyperphosphatemia In Chronic Kidney Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen - OPKO Health - Panion & Bf Biotech - Sanofi - Vifor Pharma For more information visit http://www.researchandmarkets.com/research/vk...osphatemia
OPK: 9.63 (+0.21), AMGN: 160.67 (+3.15)
